Methods Global gene and miRNA expression profiles were assessed using genome-wide
RNA and miRNA microarray technology in bone marrow mononuclear cells. Fifty-one …

Background Tumor cells have evolved complex strategies to escape immune surveillance, a
process which involves NK cells and T lymphocytes, and various immunological factors …

Tyrosine kinase inhibitors (TKIs) have vastly and irreversibly changed the course of chronic
myelogenous leukemia (CML) treatment. The vast majority of these CML cases present in …

The treatment of Chronic Myelogenous Leukaemia (CML) has been revolutionized by the
introduction of Tyrosine Kinase Inhibitors (TKIs) and represents a new paradigm for the …

Most patients with chronic myeloid leukemia have deep and durable responses when
treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs). Imatinib (the first approved TKI) …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Tyrosine kinase inhibitors (TKIs) have dramatically improved treatment outcomes in chronic
myeloid leukemia (CML), but a proportion of patients fail to achieve optimal molecular …

Chronic myeloid leukemia is a malignancy of bone marrow that affects white blood cells.
There is strong evidence that disease progression, treatment responses, and overall clinical …

The introduction of protein tyrosine kinase inhibitors (TKI s) in 1998 transformed the
management of chronic myeloid leukemia (CML), leading to significantly reduced mortality …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …